Methods of Treating Inflammatory Disorders and Global Inflammation with Compositions Comprising Phospholipid Nanoparticle Encapsulations of Anti-Inflammatory Nutraceuticals
Novel process and products thereby emplace NSAIDS within nanodelivery vehicles for various indications in mammals, including humans.
1 . A nanosphere compositional structure comprising encapsulated anti-inflammatory nutraceuticals in a stable nanoparticle structure of essential phospholipids, wherein the essential phospholipids comprise at least 75% of (3-sn-phosphatidyl) choline; and fatty acids; wherein the fatty acids are liquid at room temperature and solvents; wherein the nanoparticle structure has a particle size distribution from 50 to 150 nm, and wherein the stable structure is a liquid gel.
2 . The structure of claim 1 , wherein the essential phospholipids are comprised of greater than 85% phosphatidylcholine.
3 . The structure of claim 1 , wherein the nanoparticle does not comprise a surfactant.
4 . The nanosphere compositional structure of claim 1 , wherein the encapsulated anti-inflammatory nutraceuticals are selected from the group consisting of resveratrol, cinnamaldehyde, green tea polyphenols, lipoic acid, and curcuminoids.
5 - 11 . (canceled)
12 . A composition comprising anti-inflammatory nutraceuticals wherein the anti-inflammatory nutraceuticals are encapsulated in a stable nanoparticle structure of phospholipids and fatty acids, wherein the phospholipids comprise at least 75% of (3-sn-phosphatidyl) choline; wherein the nanoparticle structure has a particle size distribution from 50 to 150 nm; wherein the fatty acids are liquid at room temperature and wherein the stable structure is a liquid gel.
13 . The composition of claim 12 , wherein the phospholipids are comprised of greater than 85% phosphatidylcholine.
14 . The composition of claim 12 , wherein the composition does not comprise a surfactant.
15 . The composition of claim 12 , wherein the composition can enter the blood stream of a mammal via the sublingual mucosa.
16 . The composition of claim 12 , wherein the composition can enter the blood stream of a mammal via the buccal mucosa.
17 . The composition according to claim 12 , wherein the encapsulated anti-inflammatory nutraceuticals are selected from the group consisting of resveratrol, cinnamaldehyde, green tea polyphenols, lipoic acid, and curcuminoids.
18 . A method of administering encapsulated anti-inflammatory nutraceuticals to a mammal, comprising encapsulating the nutraceuticals in a nanoparticle structure of phospholipids and fatty acids; wherein the nanoparticle structure has a particle size distribution from 50 to 150 nm.
19 . The method of claim 18 , comprising administering the nanoparticle structure to a mammal via the sublingual mucosa.
20 . The method of claim 18 , comprising administering the nanoparticle structure to a mammal via the buccal mucosa.
21 . The method of claim 18 , comprising administering the nanoparticle structure to a mammal across ocular barriers into ocular tissues.
22 . The method of claim 18 , comprising administering the nanoparticle structure to a mammal across dermal and epidermal barriers.
23 . The method of claim 18 , comprising administering the nanoparticle structure to a mammal directing nose-to-brain drug delivery into CNS via the intranasal route of administration wherein the Blood Brain Barrier is bypassed.